Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Audiology

Symptom Management: Hearing Loss & Narcolepsy

At a Glance

ADCA-DN hearing loss and narcolepsy require coordinated care: regular hearing tests, hearing devices or implants when appropriate, specialist-guided wakefulness treatment, planned naps, and strict precautions against driving or hazardous tasks when sleepy.

Managing the “triad” of symptoms in Autosomal Dominant Cerebellar Ataxia-Deafness-Narcolepsy Syndrome (ADCA-DN) requires focusing on two of its most life-altering features: progressive hearing loss and severe daytime sleepiness. While these symptoms can be challenging, modern audiological and sleep medicine offer several tools to help you stay connected and alert [1][2].

Addressing Progressive Hearing Loss

The hearing loss in ADCA-DN is sensorineural, meaning it involves the inner ear or the auditory nerve [3]. It is typically progressive, often starting with higher-pitched sounds and gradually affecting more of the hearing range over time [1][4].

  • Routine Monitoring: Because the loss is gradual, you should have regular audiograms (hearing tests) with an audiologist or an Otolaryngologist (an Ear, Nose, and Throat or ENT doctor) to track changes and adjust your treatment [3].
  • Hearing Aids and Communication: In the earlier stages, high-quality hearing aids can help amplify sound. Beyond devices, it is highly beneficial to utilize communication strategies such as captioning, assistive listening systems, visual alerts for your home, and communication-partner training for your family [1].
  • Cochlear Implants: For those with profound hearing loss, a cochlear implant—a device that bypasses damaged parts of the ear to stimulate the auditory nerve directly—may be an option. Small case reports in DNMT1-related disorders have shown that cochlear implants can improve hearing and daily function in some patients [1]. However, outcomes are highly individualized and depend on the health of your auditory nerve, central processing, and rehabilitation capacity [1][3].

Managing Narcolepsy and Sleepiness

The narcolepsy associated with ADCA-DN causes excessive daytime sleepiness (EDS), which can feel like an irresistible urge to sleep regardless of how much rest you got the night before [2].

  • The Importance of Sleep Studies: Your sleep specialist may use tests like polysomnography (overnight study) and the Multiple Sleep Latency Test (MSLT) for initial diagnosis [5]. These are not routine treatment-monitoring tests. They are generally only repeated when there is diagnostic uncertainty, a major change in symptoms, or a specific clinical question, while taking into account medication effects and other factors like sleep apnea [6].
  • Lifestyle Strategies: Scheduled daytime naps are a cornerstone of management. Short, planned naps can help reduce the frequency of sudden “sleep attacks,” but you should never use them as a substitute for medication or reduce your medication doses without consulting your prescriber [2][7].

Medication Options for Wakefulness

Several medications are used to help patients with narcolepsy stay awake during the day. While evidence for these drugs comes from general narcolepsy populations (and their use in ADCA-DN may be off-label), they are standard tools directed by specialists [2][8]:

  • Wake-Promoting Agents: Medications like modafinil, solriamfetol, and pitolisant are commonly prescribed to improve daytime alertness [2][9]. A specialist will manage these, as they require cardiovascular and psychiatric monitoring.
  • Cataplexy Treatment: If you experience cataplexy (sudden muscle weakness triggered by emotions), your doctor may recommend medications like low-dose antidepressants, pitolisant, or sodium oxybate [10][11].
  • Sodium Oxybate Safety Warning: This medication requires extreme caution. It is a powerful central nervous system (CNS) depressant with serious risks of respiratory depression, confusion, and falls. It must never be mixed with alcohol, opioids, or other sedatives, and it is strictly monitored through specialized distribution programs [12][13].

Living Safely with Sleepiness

Severe sleepiness is a major safety concern. It is vital to discuss your “fitness to drive” with your doctor, as sleepiness while driving is a leading cause of accidents [14][15].

  • Stop driving or operating hazardous machinery whenever you are sleepy. You must follow your local driving rules and adhere to your clinician’s or an occupational-driving assessment’s guidance [14].
  • Avoid cooking on an open flame or using sharp tools when you feel a sleep attack coming on [16].
  • Note: A narcolepsy “sleep attack” involves unintended sleep or reduced alertness. If you experience a true sudden loss of consciousness (like fainting), convulsions, prolonged unresponsiveness, or a major sudden change in alertness, do not assume it is just ADCA-DN—seek prompt medical assessment [7].

By working closely with an Audiologist, ENT, and Sleep Specialist, you can develop a comprehensive plan to manage these symptoms and maintain your safety and independence [2][1].

Common questions in this guide

How is hearing loss managed in ADCA-DN?
Progressive sensorineural hearing loss is monitored with regular audiograms. Hearing aids, captioning, assistive listening systems, visual alerts, and communication training may help, while a cochlear implant may be considered for some people with profound loss.
When might someone with ADCA-DN need a cochlear implant?
A cochlear implant may be evaluated when hearing loss is profound and hearing aids no longer provide enough benefit. An implant team considers the health of the auditory nerve, how the brain processes sound, and the person’s ability to complete rehabilitation, so results vary.
What tests are used to evaluate narcolepsy in ADCA-DN?
An overnight sleep study and a Multiple Sleep Latency Test may be used during an initial evaluation. These tests are not usually repeated for routine treatment monitoring, but a specialist may repeat them when symptoms change, the diagnosis is uncertain, or another problem such as sleep apnea needs assessment.
Which medicines may improve daytime sleepiness in ADCA-DN?
Specialists may consider modafinil, solriamfetol, or pitolisant to improve daytime alertness. Evidence for these medicines comes mainly from broader narcolepsy populations, and treatment may be off-label in ADCA-DN, so cardiovascular and mental health monitoring is important.
What should I know before taking sodium oxybate for cataplexy?
Sodium oxybate is a powerful nervous-system depressant that can cause breathing problems, confusion, and falls. It must never be combined with alcohol, opioids, or other sedatives and requires specialist prescribing and monitoring through a restricted distribution program.
Is it safe to drive if ADCA-DN causes severe daytime sleepiness?
Do not drive or operate hazardous machinery whenever you feel sleepy or have reduced alertness. Discuss driving with your clinician, follow local rules, and consider an occupational driving assessment when an objective evaluation is needed.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the current status of my hearing, and how often should we repeat my audiogram to track its progression?
  2. 2.Based on my current hearing loss, am I a candidate for hearing aids, or should we begin a consultation for a cochlear implant?
  3. 3.Which medication for daytime sleepiness—such as modafinil, solriamfetol, or pitolisant—is safest given my other neurological symptoms and medications?
  4. 4.If I experience sudden muscle weakness (cataplexy), would sodium oxybate be appropriate for me, and what are the strict requirements for its use?
  5. 5.Is it safe for me to continue driving or operating machinery, and what objective tests can we use to decide?
  6. 6.How can we coordinate my care between the sleep specialist, audiologist, and my neurologist to manage the 'triad' of symptoms effectively?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    DNMT1-associated sensory neuropathy and cerebellar ataxia: A novel variant and review of genotype-phenotype correlation.

    Menon PJ, Bogdanova-Mihaylova P, McDermott G, et al.

    Journal of the peripheral nervous system : JPNS 2023; (28(3)):508-512 doi:10.1111/jns.12560.

    PMID: 37199681
  2. 2

    European guideline and expert statements on the management of narcolepsy in adults and children.

    Bassetti CLA, Kallweit U, Vignatelli L, et al.

    European journal of neurology 2021; (28(9)):2815-2830 doi:10.1111/ene.14888.

    PMID: 34173695
  3. 3

    Autosomal dominant cerebellar ataxia, deafness, and narcolepsy (ADCA-DN) associated with progressive cognitive and behavioral deterioration.

    Walker LA, Bourque P, Smith AM, Warman Chardon J

    Neuropsychology 2017; (31(3)):292-303 doi:10.1037/neu0000322.

    PMID: 27869457
  4. 4

    Identification of a methylation profile for DNMT1-associated autosomal dominant cerebellar ataxia, deafness, and narcolepsy.

    Kernohan KD, Cigana Schenkel L, Huang L, et al.

    Clinical epigenetics 2016; (8()):91 doi:10.1186/s13148-016-0254-x.

    PMID: 27602171
  5. 5

    Excessive Daytime Sleepiness: A Clinical Review.

    Gandhi KD, Mansukhani MP, Silber MH, Kolla BP

    Mayo Clinic proceedings 2021; (96(5)):1288-1301 doi:10.1016/j.mayocp.2020.08.033.

    PMID: 33840518
  6. 6

    Cerebellar Ataxia-deafness-narcolepsy (ADCA) syndrome. Description of a variable family phenotype.

    Abenza-Abildúa MJ, Palmí-Cortés I, Ojeda-Ruiz de Luna J, et al.

    Acta neurologica Belgica 2025; (125(5)):1395-1399 doi:10.1007/s13760-025-02776-1.

    PMID: 40285998
  7. 7

    Narcolepsy: an interface among neurology, immunology, sleep, and genetics.

    Coelho FMS

    Arquivos de neuro-psiquiatria 2024; (82(6)):1-9 doi:10.1055/s-0044-1779299.

    PMID: 38565187
  8. 8

    European guideline and expert statements on the management of narcolepsy in adults and children.

    Bassetti CLA, Kallweit U, Vignatelli L, et al.

    Journal of sleep research 2021; (30(6)):e13387 doi:10.1111/jsr.13387.

    PMID: 34173288
  9. 9

    Efficacy and safety of solriamfetol for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: a systematic review and meta-analysis of clinical trials.

    Subedi R, Singh R, Thakur RK, et al.

    Sleep medicine 2020; (75()):510-521 doi:10.1016/j.sleep.2020.09.019.

    PMID: 33032062
  10. 10

    Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial.

    Szakacs Z, Dauvilliers Y, Mikhaylov V, et al.

    The Lancet. Neurology 2017; (16(3)):200-207 doi:10.1016/S1474-4422(16)30333-7.

    PMID: 28129985
  11. 11

    Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation.

    Plazzi G, Ruoff C, Lecendreux M, et al.

    The Lancet. Child & adolescent health 2018; (2(7)):483-494 doi:10.1016/S2352-4642(18)30133-0.

    PMID: 30169321
  12. 12

    Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy.

    Roth T, Dauvilliers Y, Guinta D, et al.

    Journal of sleep research 2017; (26(4)):407-414 doi:10.1111/jsr.12468.

    PMID: 27807903
  13. 13

    The Xyrem® (Sodium Oxybate) Risk Evaluation and Mitigation Strategy (REMS) Program in the USA: Results From 2016 to 2017.

    Strunc MJ, Black J, Lillaney P, et al.

    Drugs - real world outcomes 2021; (8(1)):15-28 doi:10.1007/s40801-020-00223-6.

    PMID: 33439474
  14. 14

    Driving Safety and Fitness to Drive in Sleep Disorders.

    Tippin J, Dyken ME

    Continuum (Minneapolis, Minn.) 2017; (23(4, Sleep Neurology)):1156-1161 doi:10.1212/CON.0000000000000490.

    PMID: 28777182
  15. 15

    Excessive daytime sleepiness in obstructive sleep apnea: implications for driving licenses.

    Garbarino S

    Sleep & breathing = Schlaf & Atmung 2020; (24(1)):37-47 doi:10.1007/s11325-019-01903-6.

    PMID: 31342234
  16. 16

    Excessive Daytime Sleepiness and Safety Performance: Comparing Proactive and Reactive Approaches.

    Gharibi V, Mokarami H, Cousins R, et al.

    The international journal of occupational and environmental medicine 2020; (11(2)):95-107.

    PMID: 32218557

This page is for informational purposes only and does not constitute medical advice. Your neurologist, audiologist, ENT, and sleep specialist should tailor hearing, wakefulness, medication, and driving recommendations to your situation.

Get notified when new evidence is published on Autosomal dominant cerebellar ataxia-deafness-narcolepsy syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.